Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the appointment of Michael (Mike) McDonnell as Executive Vice President and Chief Financial Officer,...
-
In the long-term follow-up study of Zolgensma® and real-world experience, it has been reported that some patients previously treated with gene therapy have been treated with SPINRAZA1,2,3The RESPOND...
-
Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative diseaseFinal...
-
If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and TOKYO, July 08, 2020 (GLOBE NEWSWIRE) --...
-
After up to 4.8 years of continuous treatment with SPINRAZA, 100 percent of children treated pre-symptomatically were alive, and none require permanent ventilationPatients continued to maintain and...
-
Full analysis of the CLE part of the LILAC study reinforces positive top-line results; participants who received BIIB059 (anti-BDCA2) demonstrated statistically significant reduction of disease...
-
The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson’s disease, Alzheimer’s disease and multiple...
-
Patients treated with VUMERITY® (diroximel fumarate) and TECFIDERA® (dimethyl fumarate) showed a significant reduction of gadolinium-enhancing lesions compared to baselineAdditional data show improved...
-
Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adultsThe longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ages...
-
CAMBRIDGE, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the pricing of two series of senior unsecured notes for an aggregate principal amount of $3.0 billion....